Pictures on asthma
Perforomist(TM) Inhalation Solution belongs to a class of medications known as long-acting beta2-adrenergic agonists (LABAs). LABAs may increase the risk of asthma-related death. Data from a large placebo-controlled US study comparing the safety of another LABA (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol may apply to formoterol (a LABA), the active ingredient in Perforomist(TM) Inhalation Solution.
Two studies show Symbicort improves lung function in COPD Symbicort also opens airways in less than 15 minutes AstraZeneca drug is rival to GlaxoSmithKline's Advair
LONDON, Oct 29 (Reuters) - AstraZeneca Plc's (AZN.L: Quote, Profile, Research, Stock Buzz) asthma drug Symbicort can also improve lung function in patients with 'smoker's lung', or chronic obstructive pulmonary disease (COPD), results of two clinical trials showed on Wednesday.
The news underpins the Anglo-Swedish company's drive to make Symbicort an important rival to GlaxoSmithKline Plc's (GSK.L: Quote, Profile, Research, Stock Buzz) top-selling product Advair.
Both are inhaled drugs combining a corticosteroid and a long-acting beta-agonist.
AstraZeneca filed an application with the U.S. Food and Drug Administration in April for approval to sell Symbicort as a treatment for COPD, in addition to asthma, ramping up the competition with Advair.
Data presented at the annual meeting of the American College of Chest Physicians in Philadelphia showed Symbicort significantly improved lung function and was well-tolerated in patients in two COPD studies
Blog Archives:
Tiled countertops
Slate tile flooring
Kitchen cabinet makers
Asthma homeopathic
Moped for sale
Dog tee shirts
Granite marble tile
Mng cabinet hardware
Copper cabinet handles
Fireplace hearth tiles
Aprilia mopeds
Countertop tile
Shirts blouses
Cabinet handle
Antique cabinet knob
Asthma emergency treatment
Gas mopeds
Electric scooter moped
Vintage tee shirt

<< Home